ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1543

Prevalence of Ultrasound Findings Suggestive of Inflammatory Arthritis in Children with Skin Psoriasis (ChildEchoPso)
Abstract Number: 1309

Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Inflammatory Bowel Disease: A Secondary Care Cross-Sectional Study
Abstract Number: 0489

Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Abstract Number: 0451

Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Abstract Number: 1139

Primary Non-adherence in Patients with Systemic Lupus Erythematosus
Abstract Number: 1673

Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Abstract Number: 0021

Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
Abstract Number: 1028

Probabilistic Linkage of a Cohort of Individuals with Symptoms Suggestive of Early Spondyloarthritis and the French National Healthcare Database
Abstract Number: 0905

Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
Abstract Number: 1635

Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
Abstract Number: 1435

Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis
Abstract Number: 1652

Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)
Abstract Number: 0901

Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence
Abstract Number: 0018

PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City
Abstract Number: 0137

PROMIS-29 Scores Are Significantly Higher in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].